Prostate cancer generally has a very good prognosis with a five-year survival of 98%. However, a subset of men will develop recurrence and metastatic castration-resistant prostate cancer (mCRPC), and occasionally metastatic disease which is resistant to androgen deprivation therapy (ADT). The prognosis of patients with distant metastatic disease is far worse, with a five-year survival rate of 30.5%. As such, genomic profiling utilizing plasma DNA or circulating tumor cells (CTCs) can help guide clinical decision making through a detailed understanding of treatment resistance profiles and metastatic potential. Further, bioinformatics and large data analysis can further delineate personalized cancer treatments for patients diagnosed with prostate cancer.